A Phase I Study of ICP-022 in Healthy Subjects
A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-022 Following Single and Multiple Escalating Dose
Sponsor: Innocare Pharma Australia Pty Ltd
Listed as NCT03189017, this PHASE1 trial focuses on Rheumatoid Arthritis and Systemic Lupus Erythematosus and remains completed. Sponsored by Innocare Pharma Australia Pty Ltd, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Aug 2019 — Sep 2019 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jun 2018 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Mar 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Innocare Pharma Australia Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .